1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-403. 2. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014;64(2):104-17. 3. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165-74. 4. Bonelli L. Epidemiology and screening: what's new? Colorectal Disease. 2015;17:10-4. 5. Society. AC. Colorectal Cancer Facts & Figures 2014-2016. . Atlanta: 2014. 6. Church J. Hereditary colorectal cancer. The ASCRS Manual of Colon and Rectal Surgery: Springer; 2014. p. 697-733. 7. Grady WM, Carethers JM. Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis. Gastroenterology. 2008;135(4):1079-99. 8. Society AC. How is colorectal cancer diagnosed? 2015 [cited 2015 2 Decembre]. Available from: http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorec…. 9. Schnekenburger M, Diederich M. Epigenetics Offer New Horizons for Colorectal Cancer Prevention. Curr Colorectal Cancer Rep. 2012;8(1):66-81. 10. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radical Biology and Medicine. 2010;49(11):1603-16. 11. Ries LAG, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, et al. SEER cancer statistics review, 1975–2005. Bethesda, MD: National Cancer Institute. 2008:1975-2005. 12. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228-33. 13. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes & Control. 2013;24(6):1207-22. 14. Research IAfC. Colorectal Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=colorectal. 15. Flood DM, Weiss NS, Cook LS, Emerson JC, Schwartz SM, Potter JD. Colorectal cancer incidence in Asian migrants to the United States and their descendants. Cancer Causes & Control. 2000;11(5):403-11. 16. Conwell T, Boscoe FP. Urban/rural disparities in cancer incidence in New York State, 2008-2012. PeerJ PrePrints, 2015 2167-9843. 17. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths. New England Journal of Medicine. 2012;366(8):687-96. 18. Heresbach D, Manfredi S, D'Halluin P N, Bretagne JF, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol. 2006;18(4):427-33. 19. VZW Cvk. Bevolkingsonderzoek dikke darmkanker 2013. Available from: https://www.bevolkingsonderzoek.be/dikkedarmkanker/professionelen-motiv…. 20. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiologic reviews. 2011;33(1):88-100. 21. Blanco GDV, Paoluzi OA, Sileri P, Rossi P, Sica G, Pallone F. Familial colorectal cancer screening: When and what to do? World journal of gastroenterology: WJG. 2015;21(26):7944. 22. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008. Am J Gastroenterol. 2009;104(3):739-50. 23. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology. 2010;17(6):1471-4. 24. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. Journal of the National Cancer Institute. 2004;96(19):1420-5. 25. Lacy AM, García-Valdecasas JC, Delgado S, Castells A, Taurá P, Piqué JM, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. The Lancet. 2002;359(9325):2224-9. 60 26. Zheng Z, Jemal A, Lin CC, Hu C-Y, Chang GJ. Comparative Effectiveness of Laparoscopy vs Open Colectomy Among Nonmetastatic Colon Cancer Patients: An Analysis Using the National Cancer Data Base. Journal of the National Cancer Institute. 2015;107(3). 27. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. Journal of Clinical Oncology. 2009;27(6):872-7. 28. Rullier E, Denost Q, Vendrely V, Rullier A, Laurent C. Low Rectal Cancer: Classification and Standardization of Surgery. Diseases of the Colon & Rectum. 2013;56(5):560-7. 29. Heald RJ, Moran BJ, Ryall RH, Sexton R, MacFarlane JK. Rectal cancer: The basingstoke experience of total mesorectal excision, 1978-1997. Archives of Surgery. 1998;133(8):894-8. 30. Martin ST, Heneghan HM, Winter DC. Systematic review of outcomes after intersphincteric resection for low rectal cancer. British Journal of Surgery. 2012;99(5):603-12. 31. Mulsow J, Winter DC. Sphincter preservation for distal rectal cancer--a goal worth achieving at all costs? World J Gastroenterol. 2011;17(7):855-61. 32. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA: A Cancer Journal for Clinicians. 2014;64(4):252-71. 33. Marques I, Araujo A, de Mello RA. Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol. 2013;19(44):7955-71. 34. Feng Q-Y, Wei Y, Chen J-W, Chang W-J, Ye L-C, Zhu D-X, et al. Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases. World journal of gastroenterology: WJG. 2014;20(15):4263. 35. Neoadjuvant Treatment in Rectal Cancer: Actual Status. Chemotherapy Research and Practice. 2011;2011. 36. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. Journal of Clinical Oncology. 2005;23(9):2038-48. 37. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res. 2004;117:3-32. 38. Paku S. Current concepts of tumor-induced angiogenesis. Pathol Oncol Res. 1998;4(1):62-75. 39. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvascular research. 1977;14(1):53-65. 40. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA: a cancer journal for clinicians. 2010;60(4):222-43. 41. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010;10(7):505-14. 42. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62. 43. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039-51. 44. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature medicine. 2001;7(9):987-9. 45. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. Journal of Clinical Oncology. 2013;31(17):2205-18. 46. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre‐Clinical Models. Microcirculation (New York, NY : 1994). 2010;17(3):206-25. 47. Algire GH. An Adaptation of the Transparent-Chamber Technique to the Mouse. Journal of the National Cancer Institute. 1943;4(1):1-11. 48. Buades A, Coll B, Morel JM. A Review of Image Denoising Algorithms, with a New One. Multiscale Modeling & Simulation. 2005;4(2):490-530. 49. Reitan NK, Thuen M, Goa PE, de Lange Davies C. Characterization of tumor microvascular structure and permeability: comparison between magnetic resonance imaging and intravital confocal imaging. Journal of Biomedical Optics. 2010;15(3):036004. 50. Teicher BA. Role of angiogenesis in the response to anticancer therapies. Drug Resist Updat. 1998;1(1):59-61. 51. Telfer BA. Application of the dorsal window chamber to tumour vasculature manipulation studies.: The University of Manchester; 2012. 52. Dewhirst MW, Cao Y, Li CY, Moeller B. Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiotherapy and Oncology. 2007;83(3):249-55. 61 53. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer research. 1999;59(14):3374-8. 54. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61(6):2413-9. 55. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553-63. 56. Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH, et al. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res. 2006;66(23):11409-15. 57. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer. Cancer Research. 2005;65(10):4389-400. 58. Actueel SG. Cediranib en Olaprib 2016. Available from: http://kanker-actueel.nl/olaparib-plus-cedinarib-lijkt-doorbraak-bij-co…. 59. Lorusso P, Shields AF, Gadgeel S, Vaishampayan U, Guthrie T, Puchalski T, et al. Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Invest New Drugs. 2011;29(6):1395-405. 60. Satoh T, Yamaguchi K, Boku N, Okamoto W, Shimamura T, Yamazaki K, et al. Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. Invest New Drugs. 2012;30(4):1511-8. 61. Sciences NCfAT. AstraZenica AZD2171 (Cediranib) [cited 2015 14-12]. Available from: https://ncats.nih.gov/files/AZD2171.pdf. 62. Agency EM. On 29 July 2014, orphan designation (EU/3/14/1303) was granted by the European Commission to AstraZeneca AB, Sweden, for cediranib for the treatment of ovarian cancer.: European Union; 2014 [cited 2016]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orpha…. 63. Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol. 2012;30(29):3596-603. 64. Kato T, Muro K, Yamaguchi K, Bando H, Hazama S, Amagai K, et al. Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. Ann Oncol. 2012;23(4):933-41. 65. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30(29):3588-95. 66. Cunningham D, Wong RP, D'Haens G, Douillard JY, Robertson J, Stone AM, et al. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br J Cancer. 2013;108(3):493-502. 67. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155-9. 68. Hori K, Saito S, Tamai M. Effect of irradiation on neovascularization in rat skinfold chambers: implications for clinical trials of low-dose radiotherapy for wet-type age-related macular degeneration. International Journal of Radiation Oncology* Biology* Physics. 2004;60(5):1564-71. 69. Potiron VA, Abderrahmani R, Clement-Colmou K, Marionneau-Lambot S, Oullier T, Paris F, et al. Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer. PloS one. 2013;8(12):e84076. 70. Ceelen W, Smeets P, Backes W, Van Damme N, Boterberg T, Demetter P, et al. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. International journal of radiation oncology, biology, physics. 2006;64(4):1188-96. 71. Lan J, Wan XL, Deng L, Xue JX, Wang LS, Meng MB, et al. Ablative hypofractionated radiotherapy normalizes tumor vasculature in lewis lung carcinoma mice model. Radiation research. 2013;179(4):458-64. 62 72. Imaizumi N, Monnier Y, Hegi M, Mirimanoff RO, Ruegg C. Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting. PloS one. 2010;5(6):e11084. 73. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-Induced Vascular Damage in Tumors: Implications of Vascular Damage in Ablative Hypofractionated Radiotherapy (SBRT and SRS). Radiation research. 2012;177(3):311-27. 74. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts. Br J Radiol. 2008;81 Spec No 1:S21-7. 75. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Molecular cancer therapeutics. 2007;6(2):599-606. 76. Bozec A, Formento P, Lassalle S, Lippens C, Hofman P, Milano G. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer. 2007;97(1):65-72. 77. Laschke MW, Vollmar B, Menger MD. The dorsal skinfold chamber: window into the dynamic interaction of biomaterials with their surrounding host tissue. Eur Cell Mater. 2011;22:147-64; discussion 64-7. 78. Debergh I, Pattyn P, Ceelen W. Microvascular effects of the low molecular weight heparins in a colorectal xenograft model: an intravital microscopy study. J Surg Res. 2015;194(2):488-95. 79. Laschke MW, Elitzsch A, Vollmar B, Menger MD. In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopy. Fertility and Sterility. 2005;84, Supplement 2:1199-209. 80. Baker M, Wayland H. On-line volume flow rate and velocity profile measurement for blood in microvessels. Microvascular research. 1974;7(1):131-43. 81. Norrby K. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis. Microvascular research. 1998;55(1):43-53. 82. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3(1):1-7. 83. Tozer GM, Ameer-Beg SM, Baker J, Barber PR, Hill SA, Hodgkiss RJ, et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv Drug Deliv Rev. 2005;57(1):135-52. 84. Ghasemi A, Zahediasl S. Normality Tests for Statistical Analysis: A Guide for Non-Statisticians. International Journal of Endocrinology and Metabolism. 2012;10(2):486-9. 85. Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, et al. AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer cell. 2007;11(1):83-95. 86. Maeda A, Leung MKK, Conroy L, Chen Y, Bu J, Lindsay PE, et al. In Vivo Optical Imaging of Tumor and Microvascular Response to Ionizing Radiation. PloS one. 2012;7(8):e42133. 87. Daniel RA, Fisher M, Flores-Merino MV, Battaglia G, Ryan AJ, Blakey DC, et al. Effects of the isoforms of the angiogenic growth factor VEGF on neo-vascularization and tumor response to the tyrosine kinase inhibitor cediranib. Cancer Research. 2011;71(8 Supplement):3279-. 88. Jiang Y, Allen D, Kersemans V, Devery AM, Bokobza SM, Smart S, et al. Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture. Lung Cancer. 2015;90(2):191-8. 89. Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Jamin Y, Ryan AJ, et al. Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. International journal of cancer Journal international du cancer. 2012;131(8):1854-62. 90. Vajkoczy P, Ullrich A, Menger MD. Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. Neoplasia (New York, NY). 2000;2(1-2):53-61. 91. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 1994;54(17):4564-8. 92. Biel NM, Lee JA, Sorg BS, Siemann DW. Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis. Vascular Cell. 2014;6:17-. 93. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145-7. 94. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013;110(47):19059-64. 63 95. Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013;19(9):1178-83. 96. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012;72(2):402-7. 97. Jain RK. ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA. Cancer cell. 2014;26(5):605-22. 98. LTD. X. SMALL ANIMAL RADIATION RESEARCH PLATFORM (SARRP). 2016. 99. Maeda A, DaCosta RS. Optimization of the dorsal skinfold window chamber model and multi-parametric characterization of tumor-associated vasculature. IntraVital. 2014;3(1):e27935. 100. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 2011;11(2):135-41. 101. Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol. 2012;227(4):404-16. 102. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10):2943-8. 103. Faruque LI, Lin M, Battistella M, Wiebe N, Reiman T, Hemmelgarn B, et al. Systematic Review of the Risk of Adverse Outcomes Associated with Vascular Endothelial Growth Factor Inhibitors for the Treatment of Cancer. PloS one. 2014;9(7):e101145.